Some treatments can be harsh on the skin and cause irritation or sensitivity Key Takeaway Based on the available evidence, it is difficult to say which is the best option- glutathione skin whitening treatment or other pigmentation removal treatments
gastric/esophageal/GEJ adenocarcinoma)Phase 2investigator-sponsored ongoing (NCT06251973)USGraft-versus-host disease (GvHD prevention)expanding development MiNK-215MiNK-215 / FAP / IL-15 armored FAP-CAR-iNKT cell therapy / OncologySolid tumors (NSCLC, CRC liver metastases)PreclinicalIND-enabling studies underway MiNK-413MiNK-413 / BCMA / IL-15 armored BCMA-CAR-iNKT cell therapy / OncologyMultiple myelomaPreclinical PRAME TCR-iNKTPRAME / TCR-engineered iNKT cell therapy / OncologyPediatric cancers/solid tumorsPreclinicalIND-enabling 4assets bitopertinGlyT1 / Small Molecule / HematologyErythropoietic Protoporphyria (EPP) and X-linked Protoporphyria (XLP)Phase 3OngoingGlobalDiamond-Blackfan AnemiaPhase 2OngoingUS DISC-0974DISC-0974 / Hemojuvelin (HJV) / Monoclonal Antibody / HematologyAnemia of Myelofibrosis (MF)Phase 2OngoingGlobalAnemia of Chronic Kidney Disease (CKD)Phase 1/Phase 2OngoingGlobalAnemia of Inflammatory Bowel Disease (IBD)Phase 2PlannedGlobal DISC-3405DISC-3405 / TMPRSS6 (Matriptase-2) / Monoclonal Antibody / HematologyPolycythemia Vera (PV)Phase 2OngoingGlobalSickle Cell Disease (SCD)Phase 1bOngoingGlobal DISC-0998DISC-0998 / Hemojuvelin (HJV) / Monoclonal Antibody / HematologyInflammatory-disease-associated anemiaPreclinicalOngoingGlobal 4assets 4assets SelinexorKPT-330 / XPOVIO / XPO1 (Exportin 1) / Small Molecule / OncologyMultiple MyelomaMarketedActiveUSGlobalEndometrial CancerPhase 3ActiveUSGlobalMyelofibrosisPhase 3ActiveUSGlobal EltanexorKPT-8602 / XPO1 (Exportin 1) / Small Molecule / OncologyMyelodysplastic NeoplasmsPhase 2PausedUSColorectal CancerPhase 2PausedUSProstate CancerPhase 2PausedUS KPT-9274KPT-9274 / PAK4 / NAMPT / Small Molecule / OncologySolid Tumors & LymphomaPhase 1PausedUS VerdinexorKPT-335 / XPO1 (Exportin 1) / Small Molecule / Veterinary Oncology / Infectious DiseasesCanine LymphomaMarketedActiveUS 4assets IFx-2.0IFx-Hu2.0 / Innate Immune System / Personalized Cancer Vaccine / Innate Immune Agonist / OncologyAdvanced or Metastatic Merkel Cell Carcinoma (1st line, adjunctive to pembrolizumab)Phase 3OngoingUnited StatesMerkel Cell Carcinoma of Unknown Primary (MCCUP)Phase 1/Phase 2OngoingUnited States TBS-2025KVA12123 / VISTA / Monoclonal Antibody / OncologyAdvanced Solid Tumor CancerPhase 1OngoingUnited StatesmutNPM1 Acute Myeloid Leukemia (AML)Phase 1/Phase 2PlannedUnited States Bi-functional ADCsMyeloid-derived suppressor cells (MDSCs) / Antibody-Drug Conjugate (ADC) / OncologySolid TumorsPreclinicalOngoingUnited States REM-001Unknown / Photodynamic Therapy / OncologyCutaneous Metastatic Breast Cancer (CMBC)Phase 3OngoingUnited States 4assets PAS-004PAS-004 / MEK 1/2 / Macrocyclic Small Molecule / Oncology / Rare DiseasesNeurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN)MAPK pathway-driven advanced solid tumors PAS-003PAS-003 / 51 Integrin / Monoclonal Antibody / NeurologyAmyotrophic Lateral Sclerosis (ALS) PAS-001PAS-001 / C4A / Small Molecule / PsychiatrySchizophrenia PAS-002PAS-002 / NeurologyMultiple Sclerosis (MS) 4assets ZiftomenibKO-539 / KOMZIFTI / Menin-KMT2A/MLL interaction / Small molecule / Hematologic MalignanciesR/R NPM1-mutated AMLNewly Diagnosed AMLFLT3-mutated AML DarlifarnibKO-2806 / Farnesyl transferase / Small molecule / OncologyClear cell renal cell carcinoma (ccRCC)Solid tumors TipifarnibFarnesyl transferase / Small molecule / OncologyHRAS-mutant Head and Neck Squamous Cell Carcinoma (HNSCC)PIK3CA-dependent HNSCC KO-7246KO-7246 / Menin / Small molecule / CardiometabolicDiabetesCardiometabolic disease 4assets 4assets 4assets SAT-3247SAT-3247 / AAK1 / Small molecule / Degenerative muscle diseasesDuchenne Muscular Dystrophy (DMD)Facioscapulohumeral Muscular Dystrophy (FSHD) SAT-3153SAT-3153 / Notch polarity kinase / Small molecule / Degenerative muscle diseasesDuchenne Muscular Dystrophy (DMD) BertilimumabiCo-008 / Eotaxin-1 (CCL11) / Monoclonal antibody / ImmunologyBullous Pemphigoid iCo-019iCo-019 / Fungal cell membrane / Small molecule (Oral Amphotericin B) / Infectious DiseasesFungal infections 4assets GivastomigCLDN18.2 x 4-1BB / Bispecific Antibody / OncologyGastric CancerGastrointestinal Malignancies RagistomigPD-L1 x 4-1BB / Bispecific Antibody / OncologySolid Tumors UliledlimabCD73 / Monoclonal Antibody / OncologyCancer VIS-101VEGF-A x ANG-2 / Bispecific Antibody / OphthalmologyWet Age-Related Macular Degeneration (AMD)Diabetic Macular Edema (DME) 4assets NEO100NEO-100 / Unknown / Small Molecule / Oncology, NeurologyMalignant GliomasGrade 4 AstrocytomaParkinson's Disease NEO212NEO-212 / DNA / Small Molecule Conjugate / OncologyMalignant Gliomas NEO214NEO-214 / DR5, PDE4 / Small Molecule Conjugate / OncologyGlioblastoma (GBM)Multiple Myeloma NEO400NEO-400 / Unknown / Small Molecule Conjugate / Dermatology, OncologyUV-Induced Skin DamageTopical Oncology 4assets TaletrectinibIBTROZI / ROS1 / Small Molecule / OncologyAdvanced ROS1+ NSCLC SafusidenibmIDH1 / Small Molecule / OncologyDiffuse IDH1-mutant gliomaAstrocytomaOligodendroglioma NUV-1511NUV-1511 / Undisclosed / Drug-Drug Conjugate (DDC) / OncologyAdvanced solid tumors NUV-868NUV-868 / BET (BD2-selective) / Small Molecule / OncologyAdvanced solid tumors 4assets NarsoplimabOMS721 / Yartemlea / MASP-2 / Monoclonal antibody / Hematology / Complement-Mediated DiseasesHematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) ZaltenibartOMS906 / MASP-3 / Monoclonal antibody / Hematology / NephrologyParoxysmal nocturnal hemoglobinuria (PNH)C3 glomerulopathy OMS1029OMS1029 / MASP-2 / Biologic / Complement-Mediated Diseases OMS527OMS527 / PDE7 / Small molecule / AddictionCocaine use disorder 4assets leniolisibJoenja napazimoneKL1333 conestat alfaRUCONEST 4assets UlixacaltamidePRAX-944 / T-type calcium channel / Small molecule / NeurologyEssential Tremor RelutriginePRAX-562 / Persistent sodium current (NaV) / Small molecule / NeurologyDevelopmental and Epileptic Encephalopathies (DEEs)SCN2A-DEESCN8A-DEE VormatriginePRAX-628 / Sodium channels (NaV) / Small molecule / NeurologyFocal Onset EpilepsyEpilepsy ElsunersenSCN2A mRNA / Antisense oligonucleotide (ASO) / NeurologySCN2A Developmental and Epileptic Encephalopathy 4assets 4assets ABBV-RGX-314surabgene lomparvovec / sura-vec RGX-121clemidsogene lanparvovec / NAVSUNLI 4assets ZovegalisibRLY-2608 / Mutant PI3K / Small molecule / Oncology & Genetic DiseaseHR+/HER2- metastatic breast cancer (PI3K-mutated)Phase 3ActiveGlobalPIK3CA-driven vascular malformations/anomaliesPhase 1ActiveGlobal LirafugratinibRLY-4008 / FGFR2 / Small molecule / OncologyFGFR2-altered solid tumorsClinicalOut-licensedGlobal RLY-8161RLY-8161 / NRAS / Small molecule / OncologyNRAS-driven solid tumorsPreclinicalActiveGlobal Fabry disease programUndisclosed / Non-inhibitory chaperone / Genetic DiseaseFabry diseasePreclinicalActiveGlobal 4assets IMCIVREEsetmelanotide bivamelagonLB54640 Preclinical small moleculesCongenital hyperinsulinism (CHI) 4assets SCY-770PXL-770 / AMP-activated protein kinase (AMPK) / Small Molecule / Rare Diseases / NephrologyAutosomal Dominant Polycystic Kidney Disease (ADPKD)Phase 2ActiveGlobal SCY-247SCY-247 / 1,3-beta-glucan synthase / Small Molecule / Infectious DiseasesTreatment and Prevention of Invasive Fungal InfectionsPhase 1ActiveUnited States Fungerp analogs1,3-beta-glucan synthase / Small Molecule / Infectious DiseasesTreatment of resistant fungiPreclinicalActiveGlobal IbrexafungerpSCY-078 / BREXAFEMME / 1,3-beta-glucan synthase / Small Molecule / Infectious DiseasesVulvovaginal candidiasis (VVC) and Recurrent VVCApprovedActiveUnited StatesInvasive Candidiasis (IC)Phase 3ActiveGlobal 4assets SEP-479SEP-479 / PTH1R / Small Molecule / EndocrinologyHypoparathyroidismPhase 1Active SEP-631SEP-631 / MRGPRX2 / Small Molecule / Immunology and InflammationChronic spontaneous urticaria (CSU)Phase 1ActiveOther mast cell diseasesPhase 1Active TSHR ProgramTSHR / Small Molecule / EndocrinologyGraves' diseasePreclinicalActiveThyroid eye diseasePreclinicalActive Novo Nordisk Partnered ProgramsGLP-1R, GIPR, GCGR, Undisclosed / Small Molecule / Metabolic DiseasesMetabolic diseasesDiscoveryActive 4assets SPC-15SPC-15 / 5-HT4 receptor agonist / Small Molecule / PsychiatryPTSD and stress-induced anxiety disordersPreclinicalActiveGlobal SP-26SP-26 / NMDA receptor antagonist / Implant / NeurologyFibromyalgia and chronic painPreclinicalActiveGlobal SPC-14SPC-14 / Unknown / Small Molecule / NeurologyAlzheimer's diseasePreclinicalActiveGlobal SPU-16SPU-16 / Unknown / Peptide / NeurologyMultiple sclerosisPreclinicalActiveGlobal 4assets patidegibSGT-610 / Hedgehog signaling pathway (SMO) / Small molecule / DermatologyGorlin syndrome (prevention of new BCC lesions)High-frequency basal cell carcinoma (BCC) erlotinibSGT-210 / EGFR / Small molecule / DermatologyUndisclosed indications tretinoin and benzoyl peroxide cream, 0.1%/3%TWYNEO / Retinoid receptors / Bacterial proteins / Small molecule / DermatologyAcne vulgaris benzoyl peroxide cream, 5%EPSOLAY / Bacterial proteins / Small molecule / DermatologyInflammatory lesions of rosacea 4assets 4assets TSC-100TSC-100 / HA-1 / TCR-T Cell Therapy / Hematologic MalignanciesAcute Myeloid Leukemia (AML) (Post-HCT Relapse Prevention)Phase 1ActiveUnited StatesAcute Lymphoblastic Leukemia (ALL) (Post-HCT Relapse Prevention)Phase 1ActiveUnited StatesMyelodysplastic Syndromes (MDS) (Post-HCT Relapse Prevention)Phase 1ActiveUnited States TSC-101TSC-101 / HA-2 / TCR-T Cell Therapy / Hematologic MalignanciesAcute Myeloid Leukemia (AML) (Post-HCT Relapse Prevention)Phase 1ActiveUnited StatesAcute Lymphoblastic Leukemia (ALL) (Post-HCT Relapse Prevention)Phase 1ActiveUnited StatesMyelodysplastic Syndromes (MDS) (Post-HCT Relapse Prevention)Phase 1ActiveUnited States ImmunoBank TCR-T CandidatesT-Plex / Multiple Targets (e.g., PRAME, HPV16, MAGE-A1) / Multiplexed TCR-T Cell Therapy / OncologySolid TumorsPhase 1ActiveUnited States Novel TargetsUnidentified Autoantigens / Targeted Therapeutics / Autoimmune DisordersCrohn's DiseaseDiscoveryActiveUnited States 4assets 4assets VXA-CoV2-3.3VXA-CoV2-3.3 / SARS-CoV-2 / Oral recombinant adenovirus vaccine / Infectious DiseasesCOVID-19 Norovirus Oral Vaccine CandidateNorovirus (GI.1 and GII.4) / Oral recombinant adenovirus vaccine / Infectious DiseasesNorovirus InfectionAcute Gastroenteritis Seasonal Influenza Oral Vaccine CandidateVXA-A1 / Influenza Virus / Oral recombinant adenovirus vaccine / Infectious DiseasesSeasonal Influenza HPV Therapeutic Vaccine CandidateHuman Papillomavirus (HPV) / Oral recombinant therapeutic vaccine / OncologyHPV-associated Cancers / Immuno-oncology 4assets AzetukalnerXEN1101 / Kv7.2/Kv7.3 potassium channel opener / Small Molecule / Neurology and PsychiatryFocal Onset Seizures (FOS)Phase 3OngoingGlobalPrimary Generalized Tonic-Clonic Seizures (PGTCS)Phase 3OngoingGlobalMajor Depressive Disorder (MDD)Phase 3OngoingGlobal XEN1120XEN1120 / Kv7 potassium channel opener / Small Molecule / PainPainPhase 1OngoingUnited States XEN1701XEN1701 / NaV1.7 sodium channel modulator / Small Molecule / PainPainPhase 1OngoingUnited States NBI-921355NBI-921355 / NaV1.2 / NaV1.6 sodium channel inhibitor / Small Molecule / NeurologyEpilepsyPhase 1OngoingGlobal 3assets SabirnetugACU193 / toxic soluble amyloid beta oligomers (AOs) / humanized monoclonal antibody
Some users report experiencing unpleasant aftertastes, commonly referred to as "sulfur burps." 3
Oral semaglutide is a peptide formulation
Understanding these potential changes is essential for accurate interpretation of test results and appropriate clinical decision-making
Your first month begins with an initial consultation to assess your health, weight loss goals, and any medical conditions
